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Abstract: Electroporation is a safe and efficient method to transfect human tooth germ stem cells (hTGSCs), which are mainly
mesenchymal stem cells (MSCs). In this study, pluronic F68 (PF68), a nonionic and low-foaming surfactant, was used for the first time
to increase the transfection efficiency in electroporation of hTGSCs. Our results revealed that when PF68 was used in the preincubation,
electroporation, and recovery medium, it dramatically increased transfection efficiency. Moreover, use of PF68 did not alter the
differentiation capacity of hTGSCs, whereas cells electroporated without PF68 had significantly lower expression of Oct-4, pluripotency
marker gene, and alkaline phosphatase (ALP) activity upon osteogenic differentiation. We found that PF68 increases transfection
efficiency in both electroporation and chemical transfection of cancer cells lines MCF-7 and HeLa. The study suggested that PF68 might
be a safe and reliable chemical to use for increasing transfection efficiency during electroporation and chemical transfections.
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1. Introduction
Mesenchymal stem cells (MSCs) are being investigated
for their potential use in cell-based therapies and tissue
engineering applications. MSCs can be isolated from
various tissues such as adipose, cartilage, skin, liver, and
bone marrow (Campagnoli et al., 2001; Zuk et al., 2002). It
was recently found that MSCs isolated from extracted third
molars show MSC and NSC (neural stem cell) properties
(Graziano et al., 2008; Yalvac et al., 2010). In addition,
the isolation procedure for MSCs from dental tissues is
easier than isolation from bone marrow (Ikeda et al., 2008;
Yalvac et al., 2009). We previously showed that PF68, a
water-soluble block copolymer, increases differentiation
capacity of hTGSCs (Dogan et al., 2012; Tasli et al., 2013)
and protects them from the adverse effects of long-term
cryopreservation (Dogan et al., 2013). We also described
the methods for efficient gene delivery into these cells
using electroporation (Yalvac et al., 2009). In this study,
we improved the transfection efficiency by adding PF-68
during electroporation. PF68 is an effective agent in the
functional recovery of permeabilized cell membranes
and enhances membrane resealing in vivo and in vitro
(Hartikka et al., 2001).

The drawbacks of electroporation usually include
altered cell physiology, gene expression, and cell
proliferation after electroporation, which might stem from
damage to the cell membranes during electroporation. In
this study, we showed that PF68 increases cell survival and
transfection efficiency in both hTGSCs and cancer cell lines
MCF-7 and HeLa. Pre- and postincubation with PF68, in
addition to the presence of PF68 during electroporation,
was most beneficial for the electroporated cells, minimally
altering the pluripotent state and differentiation capacity
of the hTGSCs.
2. Materials and methods
2.1. Isolation and characterization of hTGSCs
The human impacted third molar tooth germs used for
this study were previously isolated and cryopreserved
by our group (Yalvac et al., 2011), according to the
procedures established in our laboratory. Human tooth
germs were taken from the wisdom teeth of a 13-yearold patient following routine dental treatment. Following
approval from the Institutional Ethics Committee of
Yeditepe University, Turkey (decision no.: 2010-020),
written consent was obtained from the patient and his
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parents (Yalvac et al., 2009, 2010). Passage-1 hTGSCs were
maintained in growth medium (GM) containing Dulbecco’s
modified essential medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1%
PSA (penicillin, streptomycin, and amphotericin) solution
and incubated at 37 °C in a humidified atmosphere of 5%
CO2 in the incubator.
Prior to use in our experiments, the specific surface
antigens of hTGSCs were characterized by flow cytometry.
The cells were incubated with primary antibodies
against CD29 (cat. no.: BD556049), CD34 (cat. no.: SC51540), CD45 (cat. no.: SC-70686), CD90 (cat. no.: SC53456), CD105 (cat. no.: SC-71043), CD133 (cat. no.:
SC-65278), and CD73 (cat. no.: BD 550256) (SC = Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA; BD
= BD Biosciences, Franklin Lakes, NJ, USA) in phosphate
buffered saline (PBS) for 45 min. After washing with PBS,
the cells were incubated with fluorescein isothiocyanate
(FITC) conjugated secondary antibodies (cat. no.: SC2989) at 4 °C for 45 min followed by washing with PBS
and analysis with flow cytometry equipment (Becton–
Dickinson FACSCalibur, San Jose, CA, USA).
2.2. Preparation of pluronic PF68
Pluronic PF68 (Badische Anilin und Soda-Fabrik,
Germany) was dissolved in PBS at 10% (w/v) concentration.
Pluronic PF68 forms a gel structure at room temperature
for high concentrations. A 10% (w/v) concentration was
diluted to 1% concentration in PBS, sterilized with 0.2
µm filter, and kept at 4 °C. Four concentrations (0.01%,
0.02%, 0.05%, and 0.1%) of pluronic PF68 were prepared
in growth media and tested for toxicity on hTGSCs and
MSCs and HeLa cells by culturing the cells in 96-well
plates (5000 cells/well) followed by the addition of four
concentrations of pluronic PF68. The cell viability of
hTGSCs was measured by the 3-(4,5-dimethyl-thiazol2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfo-phenyl)2H-tetrazolium (MTS) assay (CellTiter96 AQueousOne
Solution; Promega, Southampton, UK) after 24 h,
according to the manufacturer`s instructions.

2.3. Electroporation of hTGSCs and HeLa and MCF-7
cells
Optimum electroporation conditions for hTGSCs were
determined by our group (Yalvac et al., 2009). Briefly,
hTGSCs (5 × 106 cells) were electroporated using
exponential-decay pulses (300 V, 500 µF) with 5 µg of
pEGFP-N2 plasmid DNA (Promega, USA) in 0.4 mm
cuvettes containing 400 µL of RPMI-1640 medium (Gibco,
CA, USA). For HeLa and MCF-7 cells, voltages were 140
V and 250 V, respectively. All electroporation analysis was
done by using Gene Pulser II equipment (Biorad, USA).
Electroporated cells were plated in six- and ninety-six–
well plates. The cell viability and transfection efficiency
were measured by MTS-assay and flow cytometry
analysis, respectively. To determine the effect of PF68 on
electroporation of hTGSCs, the experimental groups were
designed as shown in the Table.
In all groups, a 0.05% final concentration of PF68 was
used. Preincubation time and recovery time with PF68
were 6 h and 48 h, respectively.
2.4. Chemical transfection
Chemical transfection of MCF-7 and HeLa cells was
performed by using Turbofect transfection reagent
(Thermo Scientific, USA), according to the manufacturer’s
instructions, in the presence and absence of PF68 used at
a final concentration of 0.05% in the transfection medium.
2.5. Real-time PCR analysis
Total mRNA from hTGSCs was isolated using High Pure
RNA isolation kit (Roche, USA), and complementary
DNAs (cDNAs) were synthesized by using High Fidelity
cDNA synthesis kit (Roche, USA), according to the
manufacturer’s instructions. Real-time PCR conditions,
Taqman primers, and probes for Oct-4 were used, as
previously published by our group (Yalvac et al., 2010).
2.6. Differentiation hTGSCs
Electroporated hTGSCs were induced to differentiate into
osteogenic cells, as described previously (Dogan et al.,
2012). Briefly, the cells were seeded into a 6-well plate at a
concentration of 60,000 cells/well followed by the addition
of premade osteogenic differentiation medium consisting

Table. Experimental conditions.
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Groups

Conditions

Group 1 (G1)

Electroporation without PF68

Group 2 (G2)

Electroporation with PF68 + PF68 in recovery

Group 3 (G3)

Electroporation without PF68 + PF68 in recovery

Group 4 (G4)

Electroporation with PF68 + no PF68 in recovery

Group 5 (G5)

Preincubation with PF68 + electroporation with PF68 + PF68 in recovery
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of 50 µg/mL ascorbic acid (Sigma, USA), 50 nM β-glycerol
22 phosphate (Sigma, USA), and 10−8 µM dexamethasone
(DXM) (Sigma, USA). The cells were incubated for 10
days at 37 °C in a humidified atmosphere of 5% CO2 in
the incubator. Differentiation medium was changed every
other day.
2.7. ALP activity assay
On the tenth day of osteogenic differentiation, the cells
were trypsinized and centrifuged at 1000 rpm for 5 min.
The pellet was resuspended in 500 µL of cell lysis buffer
containing 0.2% (v/v) Triton-X-100 diluted in PBS and
incubated for 30 min at room temperature. Then 10 µL
of lysate was put into a 96-well plate, and 90 µL of ALP
solution (Randox ALP detection kit; Randox, Antrim,
UK) was added to the lysate. After 15 min, the absorbance
at 405 nm was measured to demonstrate ALP enzyme
activity by using an ELISA plate reader (Biotek, Winooski,
VT, USA).
2.8. Immunocytochemistry analysis
Differentiated cells were stained for osteocalcin (OC) and
collagen type 1 (COL1A1), as previously described (Yalvac
et al., 2013). Briefly, the cells were fixed with 2% (w/v)
paraformaldehyde by incubating at +4 °C for 30 min,
followed by permeabilization of the cells by incubation
with 0.1% Triton-X100/PBS for 5 min. Nonspecific binding
of antibodies was blocked by incubating with 2% goat
serum diluted in PBS for 20 min at +4 °C by washing with
PBS three times for 5 min. The cells were incubated with
primary antibodies (OC: Santa Cruz # 30044; COL1A1:
Santa Cruz # 59772) with a 1:100 dilution overnight.
Then they were washed with PBS three times for 5 min
to remove unbound primary antibodies. Goat anti-rabbit
IgG Alexa Fluor 488 (cat. #A-11034, Life Technologies,
CA, USA) and goat anti-mouse IgG Alexa Fluor 488 (cat.
#1100, Life Technologies, CA, USA) secondary antibodies
were added to the samples and left for 1 h at 4 °C. The
cells were then washed with PBS three times for 5 min.
The nuclei of the cells were stained with 4’,6-diamidino-2phenylindole (DAPI) (AppliChem, Darmstadt, Germany).
The stained samples were observed using a fluorescent
microscope (Nikon Eclipse TE200; Nikon, Tokyo, Japan).
2.9. von Kossa staining
After 10 days of incubation with osteogenic medium in a sixwell plate, the cells were fixed with 2% paraformaldehyde
at +4 °C for 30 min and stained by using the von Kossa
method (von Kossa kit; BioOptica, Milan, Italy) followed
by observation and picturing of brown calcium deposits
under a light microscope (Nikon, Japan).
2.10. Statistical analysis
The results were given as ± standard error of the means
(SEM), and P values smaller than 0.05 were considered
statistically significant. All values were calculated using

Graph-Pad Prism 5 software (Graph-Pad, La Jolla, CA,
USA).
3. Results
3.1. Characterization of hTGSCs and incubation with
PF68
In order to determine phenotypic characters of hTGSCs,
the cells were analyzed for the MSC markers CD29, CD73,
CD90, and CD105. The results indicated that hTGSCs
were all positive for MSC markers but negative for
hematopoietic markers such as CD34, CD45, and CD133
(Figure 1).
In order to determine the cytotoxic effect of PF68
on hTGSCs, the cells were incubated with PF68 at four
different concentrations prior to electroporation. PF68 did
not show any cytotoxic effect at any concentration tested
(Figure 2).
The same concentrations were not found to cause
cytotoxicity in HeLa or MCF-7 cells (data not shown).
3.2. Electroporation with PF68
In all electroporation, the presence of PF68 increased the
transfection efficiency (Figure 3).
Cell viability of hTGSCs was higher under
electroporation conditions where PF68 was used (Figure
4a). For hTGSCs and MCF-7 cells, the highest transfection
efficiency was obtained in group 5 (40% for hTGSCs and
50% for MCF-7 cells), in which PF68 was added to growth
medium 6 h before electroporation and maintained in
electroporation medium, and then recovery medium, for
48 h (Figure 4b). For HeLa cells the transfection efficiency
was significantly higher in all PF68-treated groups (Figure
4b).
Furthermore, analysis of hTGSCs after electroporation
revealed that the cells in group 5 had a higher expression
of Oct-4 compared to group 1 (Figure 5a). ALP levels
were higher in group 5 after osteogenic differentiation,
indicating a more efficient differentiation in this group
(Figure 5b). PF68+ hTGSCs differentiated into osteogenic
cells, which was confirmed by positive COL1A1, OC,
and von Kossa stainings, which showed calcium deposits
(Figure 5c). When used in combination with Turbofect
transfection reagent at the same final concentration, PF68
significantly increased the transfection efficiency in HeLa
cells (Figure 5d).
4. Discussion
As a nonviral gene delivery method, electroporation has
been proven to be an efficient gene transfection method
that can be useful for in vitro and in vivo gene and cell
therapy applications (Gehl, 2003; Ayuni et al., 2010). We
previously optimized the electroporation conditions for
hTGSCs (Yalvac et al., 2009). In this study, we aimed to
improve the transfection efficiency in hTGSCs by using
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Figure 1. Flow analysis. The hTGSCs expressed the MSC-specific cell surface antigens (CD29, CD73, CD90, CD105) but were negative
for hematopoietic cell markers (CD34, CD45, CD133). NC: nonstained cells.

Figure 2. Toxicity test for PF68. PF68 was nontoxic on hTGSCs when used at 0.01%, 0.02%, 0.05%, and 0.1% (w/v) concentrations. In
all electroporations and chemical transfections, a 0.05% concentration was used.

PF68. The hTGSCs used in the study were MSCs-confirmed
by flow cytometry analysis. It is well known that nonviral
gene delivery systems are usually not as efficient as viral
vectors for transfecting MSCs. On the other hand, the use
of viral vectors has potential limitations such as silencing
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of the transgenes or triggering immune reactions (Ferreira
et al., 2008). Electroporation can dramatically increase the
transfection efficiency in MSCs when the most optimum
conditions are provided for the cells (Peister et al., 2004).
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Figure 3. EGFP+ electroporated cells. EGFP+ cells in all groups were pictured under inverted fluorescent microscope (Nikon Eclipse
TE200; Nikon, Tokyo, Japan) 48 h after the electroporation. Group 1 (G1): electroporation without PF68, group 2 (G2): electroporation
with PF68 + PF68 in recovery, group 3 (G3): electroporation without PF68 + PF68 in recovery, group 4 (G4): electroporation with PF68
+ no PF68 in recovery, group 5 (G5): preincubation with PF68 + electroporation with PF68 + PF68 in recovery. Scale bar: 400 µm.

Figure 4. Analysis of transfection efficiency and cell viability. a. The cell viability of hTGSCs during electroporation increased through
the addition of PF68. b. EGFP+ cells were quantified by using flow cytometry, and cell viability after electroporation was measured
by MTS test. For hTGSCs and MCF-7 cells the best results were obtained in group 5. PF68 increased the percentage EGFP+ under all
conditions. The experiments were done in triplicate and the data presented as ±SEM. *P < 0.05.
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Figure 5. Analysis of electroporated cells. a. The PF68 treated cells had a higher expression of Oct4 gene. b. Upon osteogenic
differentiation, ALP activity in PF68-treated cells was higher than in nontreated cells. Group 1 (G1): electroporation without PF68,
group 5 (G5): preincubation with PF68 + electroporation with PF68 + PF68 in recovery c. Osteogenic differentiation was confirmed by
positive COL1A1, OC, and von Kossa stainings. d. PF68 increased the transfection efficiency in HeLa cells when used in combination
with Turbofect at 0.05% concentration in the transfection medium. The experiments were done in triplicate and the data presented as
±SEM. *P < 0.05.

Previous studies showed that PF68, as a tri-block–
structured co-polymer, could reduce the membrane
capacitance during electroporation and increase the
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electroporation threshold by incorporation into the lipid
bilayer (Sharma et al., 1996). PF68 increased the delivery
of naked DNA into muscle by electroporation (Hartikka et
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al., 2001), and it helped muscle tissue restoration after in
vivo electroporation (Collins et al., 2007). PF68 is able to
interact with the lipid bilayer to provide resistance during
the electroporation process and seals the pores after
electroporation, which helps to reduce tissue injury.
In this study, we found that PF68 increases transfection
efficiency in hTGSCs. Moreover, after electroporation
in group 5, cells had higher expression of Oct-4; upon
osteogenic differentiation they had higher ALP activity
than the cells electroporated without PF68. This indicates
that preincubation of hTGSCs with PF68, as well as its
presence in the electroporation and recovery medium,
resulted in the highest transfection efficiency by minimally
altering the cellular physiology and differentiation capacity
of the cells. PF68 decreases the opening and expansion rate
of electro-pores by interacting with the hydrocarbon tails
of the lipids in the cell membrane, providing a mechanical
strength to the membranes (Tung et al., 1999).
The use of PF68 increased the transfection efficiency
in electroporation of HeLa and MCF-7 cells which are
well-known cancer cell lines widely used in biomedical
research. HeLa and MCF-7 cells were used to show the
effect of PF68 in the electroporation of cancer cell lines. The

results showed that PF68 can be used in electroporation
of hTGSCs and cancer cell lines such as HeLa and MCF7 cells. Unlike hTGSCs, cancer cell lines are easier to
transfect with liposome- or polymer-based transfection
reagents with relatively high transfection efficiencies. In
this study, we demonstrated that transfection efficiency can
be further increased when PF68 is added into transfection
medium along with the Turbofect transfection reagent.
In conclusion, this study revealed that PF68
significantly improves the efficacy of electroporation in
hTGSCs, which are difficult to transfect using transfection
reagents. Results showed that the presence of PF68 in
preincubation, electroporation, and recovery media
gives rise to the best results in electroporation of both
hTGSCs and cancer cell lines. This study might help other
researchers improve their electroporation protocols and
enhance the translational potential of electroporated cells
in gene and cell-therapy applications.
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